ORCHESTRA BIOMED HOLDINGS INC.
NASDAQ: OBIO (Orchestra BioMed Holdings, Inc.)
Kemas kini terakhir: 46 minit lalu6.97
-0.15 (-2.11%)
| Penutupan Terdahulu | 7.12 |
| Jumlah Dagangan | 551,845 |
| Harga / Jualan (P/S) | 14.70 |
| Harga / Buku (P/B) | 57.25 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,179.84% |
| EPS Cair (TTM) | -1.77 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 40.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 97.55% |
| Nisbah Semasa (MRQ) | 3.35 |
| Aliran Tunai Operasi (OCF TTM) | -54.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.16 M |
| Pulangan Atas Aset (ROA TTM) | -60.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -179.12% |
Sentimen Berita
-
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
2 hari lalu, 7:55AM
-
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
10 Nov, 3:10PM
-
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
10 Nov, 4:40PM
-
Orchestra BioMed Announces Pricing of Public Offering
05 Nov, 9:42PM
-
Orchestra BioMed Announces Proposed Public Offering
05 Nov, 3:01PM
AISkor Stockmoo
| Nilai 30% | -3.1 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | 3.4 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menaik sepanjang tahun lalu. Didagangkan hampir paras tertinggi 52 minggu. info | |
| Harga dan purata bergeraknya tersusun dalam aliran menaik. Purata bergerak utamanya mendatar. Hampir dengan purata bergerak yang meningkat. Dagangan lebih tinggi pada hari harga naik. info | |
| Corak Lilin info | NA |
| Di atas garis aliran jangka sederhana. info | |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Wang Pintar 20% | 3.0 |
| Beberapa orang dalam membeli bersih baru-baru ini. info | |
| Institusi bersih +5.72% daripada saham dalam pemfailan 13F terkini: 61 pemegang menambah, 31 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +11.0% dari 31 Aug hingga 30 Oct 2026, 7 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek meningkat. info | |
| Tiada isyarat jelas daripada sokongan dan rintangan. info | |
| Skor Akhir | 0.53 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Orchestra BioMed Holdings, Inc. | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| OBIO | - | - | - | 57.25 |
| TRML | 1 B | - | - | 4.76 |
| VRDN | - | - | - | 7.26 |
| VRCA | - | - | - | 15.60 |
| TECH | - | 0.44% | - | 5.28 |
| ABEO | - | - | - | 1.10 |
|
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 21.81% |
| % Dimiliki oleh Institusi | 49.62% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FAIN ERIC S | 5.70 | - | 20,000 | 114,000 |
| HOCHMAN DAVID P | 5.70 | - | 5,000 | 28,500 |
| PACITTI DAVID | 5.70 | - | 20,000 | 114,000 |
| TAYLOR ANDREW LAWRENCE | 5.70 | - | 1,000 | 5,700 |
| Jumlah Keseluruhan Kuantiti Bersih | 46,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 262,200 | |||
| Purata Pembelian Keseluruhan ($) | 5.70 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TAYLOR ANDREW LAWRENCE | Pegawai | 09 Nov 2026 | Beli (+) | 1,000 | 5.70 | 5,700 |
| HOCHMAN DAVID P | Pegawai | 09 Nov 2026 | Beli (+) | 5,000 | 5.70 | 28,500 |
| PACITTI DAVID | Pengarah | 09 Nov 2026 | Beli (+) | 20,000 | 5.70 | 114,000 |
| FAIN ERIC S | Pengarah | 09 Nov 2026 | Beli (+) | 20,000 | 5.70 | 114,000 |
Institusi
Pemilikan institusi: 41.73%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 61 | 5,034,559 |
| Berkurang | 31 | 1,386,397 |
| Baharu | 27 | 1,437,879 |
| Dijual habis | 11 | 569,836 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 2,732,484 | 7.0 |
| 15 Oct 2026 | 2,552,988 | 9.7 |
| 30 Sep 2026 | 2,547,249 | 7.0 |
| 15 Sep 2026 | 2,372,557 | 6.6 |
| 31 Aug 2026 | 2,460,669 | 5.8 |
| 14 Aug 2026 | 2,383,854 | 13.1 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 16 Nov 2026 | Yahoo Finance |
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 10 Nov 2026 | Yahoo Finance |
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 10 Nov 2026 | Yahoo Finance |
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).Medtronic… |
| 05 Nov 2026 | Yahoo Finance |
Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 05 Nov 2026 | Yahoo Finance |
Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 29 Oct 2026 | Yahoo Finance |
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels… |
| 22 Oct 2026 | Yahoo Finance |
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq… |
| 20 Oct 2026 | Yahoo Finance |
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday . |
| 01 Oct 2026 | Yahoo Finance |
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing… |
| 21 Sep 2026 | Yahoo Finance |
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
| 16 Sep 2026 | Yahoo Finance |
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO)… |
| 15 Sep 2026 | Yahoo Finance |
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides… |
| 02 Sep 2026 | Yahoo Finance |
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported… |
| 27 Aug 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman… |
| 20 Aug 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman… |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |